Claiming Breach of Agreement, Rosetta Genomics Ending Licensing Deal with Avatao | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics said today it is terminating a licensing deal with Avatao Biotech, accusing the Chinese diagnostic firm of material breach of an agreement.

The Israel-based molecular diagnostics firm said in a document filed with the US Securities and Exchange Commission that it delivered notice to Avatao on June 12 of its decision to terminate an agreement reached by the two companies in October covering China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.